Creation of a National Multicenter Platform for the Study of Inflammatory Myocardial Disease: Pre-MYO Cohort
Key facts
- Where
- Murcia, SpainSee the site
Where in Spain
- HCUVAMurcia, SpainContact: Domingo Pascual Figal, MDTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Fundacion para la Formacion e Investigacion Sanitarias de la Region de Murcia
- Trial code
- NCT06898762
- Record updated
- 27 March 2025
- Original description
The objectives of this project are: 1) to comprehensively characterize a large national cohort of patients with suspected myocarditis, their clinical phenotype, care management, blood and imaging biomarkers, epidemiological, environmental and genetic data; 2) to retrospectively validate the accuracy of the new hsa-RNA-Chr8:96 biomarker for the diagnosis of myocarditis compared to conventional diagnosis; 3) to identify acquired and inherited mutations, and their interaction with the environment, which explain the susceptibility to myocarditis, its severity and response to treatment; 4) to study the lower incidence in women and the influence of age, considering socio-health and genetic factors.Read full original descriptionShow less
The objectives of this project are: 1) to comprehensively characterize a large national cohort of patients with suspected myocarditis, their clinical phenotype, care management, blood and imaging biomarkers, epidemiological, environmental and genetic data; 2) to retrospectively validate the accuracy of the new hsa-RNA-Chr8:96 biomarker for the diagnosis of myocarditis compared to conventional diagnosis; 3) to identify acquired and inherited mutations, and their interaction with the environment, which explain the susceptibility to myocarditis, its severity and response to treatment; 4) to study the lower incidence in women and the influence of age, considering socio-health and genetic factors.
Inclusion: Presence of at least one compatible symptom and at least one objective finding in diagnostic tests (Figure 2), according to the consensus document of the European Society of Cardiology (1):; Clinical presentation:; Acute chest pain: pericardial or pseudo-ischemic; Dyspnea on exertion or at rest for up to 3 months; Dyspnea on exertion or at rest for 3 months - 1 year; Unexplained palpitations / arrhythmias, sudden death recovered; Unexplained cardiogenic shock; Findings in complementary tests:; ECG: new onset AV block, new onset bundle branch block, ST segment elevation/depression, T wave inversion; Elevation of TnI/TnT; Segmental or global contractility alterations not explained by other causes; Positive Lake Louise criteria in cardiac MRI (13) (Annex III Figure S1) • Patients who have given their informed consent.